GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AstraZeneca PLC (OSTO:AZN) » Definitions » Cyclically Adjusted PB Ratio

AstraZeneca (OSTO:AZN) Cyclically Adjusted PB Ratio : 9.39 (As of May. 23, 2024)


View and export this data going back to 1999. Start your Free Trial

What is AstraZeneca Cyclically Adjusted PB Ratio?

As of today (2024-05-23), AstraZeneca's current share price is kr1683.00. AstraZeneca's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was kr179.15. AstraZeneca's Cyclically Adjusted PB Ratio for today is 9.39.

The historical rank and industry rank for AstraZeneca's Cyclically Adjusted PB Ratio or its related term are showing as below:

OSTO:AZN' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 3.78   Med: 5.6   Max: 10.1
Current: 9.38

During the past years, AstraZeneca's highest Cyclically Adjusted PB Ratio was 10.10. The lowest was 3.78. And the median was 5.60.

OSTO:AZN's Cyclically Adjusted PB Ratio is ranked worse than
93.14% of 685 companies
in the Drug Manufacturers industry
Industry Median: 1.9 vs OSTO:AZN: 9.38

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

AstraZeneca's adjusted book value per share data for the three months ended in Mar. 2024 was kr251.481. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is kr179.15 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


AstraZeneca Cyclically Adjusted PB Ratio Historical Data

The historical data trend for AstraZeneca's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AstraZeneca Cyclically Adjusted PB Ratio Chart

AstraZeneca Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.33 7.32 8.24 9.33 8.20

AstraZeneca Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.16 8.95 8.70 8.20 8.11

Competitive Comparison of AstraZeneca's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - General subindustry, AstraZeneca's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AstraZeneca's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AstraZeneca's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where AstraZeneca's Cyclically Adjusted PB Ratio falls into.



AstraZeneca Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

AstraZeneca's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=1683.00/179.15
=9.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AstraZeneca's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, AstraZeneca's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=251.481/131.6000*131.6000
=251.481

Current CPI (Mar. 2024) = 131.6000.

AstraZeneca Quarterly Data

Book Value per Share CPI Adj_Book
201406 116.614 99.800 153.772
201409 115.421 100.000 151.894
201412 118.540 99.900 156.155
201503 114.490 99.600 151.274
201506 119.560 100.100 157.184
201509 114.826 100.200 150.809
201512 124.237 100.400 162.845
201603 97.179 100.400 127.378
201606 88.820 101.000 115.730
201609 88.157 101.500 114.300
201612 108.092 102.200 139.187
201703 91.464 102.700 117.202
201706 93.602 103.500 119.015
201709 86.840 104.300 109.570
201712 99.155 105.000 124.274
201803 84.027 105.100 105.214
201806 87.860 105.900 109.182
201809 84.231 106.600 103.985
201812 88.860 107.100 109.187
201903 74.266 107.000 91.340
201906 97.171 107.900 118.514
201909 90.020 108.400 109.286
201912 94.364 108.500 114.454
202003 80.852 108.600 97.975
202006 86.821 108.800 105.015
202009 82.292 109.200 99.172
202012 99.529 109.400 119.726
202103 93.908 109.700 112.655
202106 100.264 111.400 118.445
202109 221.766 112.400 259.648
202112 230.367 114.700 264.309
202203 224.337 116.500 253.414
202206 232.706 120.500 254.142
202209 247.378 122.300 266.189
202212 248.013 125.300 260.483
202303 241.918 126.800 251.076
202306 259.812 129.400 264.229
202309 266.029 130.100 269.096
202312 259.014 130.500 261.197
202403 251.481 131.600 251.481

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


AstraZeneca  (OSTO:AZN) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


AstraZeneca Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of AstraZeneca's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


AstraZeneca (OSTO:AZN) Business Description

Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its revenue.

AstraZeneca (OSTO:AZN) Headlines

From GuruFocus